
usd may pm et
summari provid precis measur analysi instrument softwar use life
scienc laboratori industri retail applic
price-to-earnings oper ep
think benefit industri geograph
product diversif spread across life scienc
industri retail end-market countri
diversif help firm maintain stabl cash flow
one end-market experi short-term
weak also benefit strong reput
product qualiti innov custom servic
softwar integr think creat repeat
custom also low leverag rel peer
see posit partial off-set increas
relianc life scienc industri china sale
jul ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
may stock trade
revenu decreas yoy
neg impact sale
china yoy local currenc higher
expect except
america yoy grew slowli
compar previou period region
oper saw sharp sale declin
asia/rest world affect
yoy follow europ yoy product
area food retail sale
significantli impact yoy local
currenc follow industri yoy
lab sale yoy
forecast sever
impact quarter total revenu declin
around expect see sale declin
core america region total
later impact also
continu weak europ part
asia expect china slowli pick
forecast sale declin around
busi disrupt due
ad drag global industri
weak food retail expect
worst-hit area year yearli
sale declin around expect ep
declin yoy assum share
stay neutral expect
prolong slowdown sale china
signific declin rest
global oper due shock
one largest exposur china
among life scienc compani coverag
univers sale make
total revenu import chines
product base largest market
larg presenc china
hold excel price power driven
high switch cost view think
popular labx softwar heavili
integr instrument custom
workflow make costli time
consum custom switch
competitor competit advantag
appar pre-tax return invest
capit consist
think lead industri
target ep
estim line histor
forward price-to-earnings averag prolong
neg impact affect
sever quarter revenu
anticip import risk
view risk see reduct
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
head divis
corpor overview mettler-toledo intern inc suppli precis measur
analysi instrument servic use laboratori sale industri food retail
applic product servic critic custom life scienc industri
pharmaceut biotech compani well contract research organ food beverag
produc chemic specialti chemic cosmet compani food retail transport
logist industri metal industri electron industri academ commun
compani report oper five segment oper sale european
oper chines oper rest world
product sever key product categori includ balanc pipett laboratori softwar
detail
laboratori balanc compani manufactur broad varieti laboratori balanc associ
analysi instrument weigh rang one ten-millionth gram kilogram
laboratori balanc primarili use pharmaceut biotechnolog test lab food chemic
cosmet academia industri
pipett pipett use laboratori dispens precis volum liquid compani
also maintain servic center key market custom period send pipett
certifi recalibr princip end market pipett pharmaceut biotech academia
analyt instrument product segment includ titrat measur chemic composit
sampl use environment research laboratori well qualiti control lab
pharmaceut food beverag industri thermal analysi system measur
materi properti function temperatur weight dimens energi flow viscoelast
properti use primarili plastic polym industri academia increasingli
pharmaceut industri ph meter densiti refractometri insrument moistur analyz
laboratori softwar labx compani pc-base laboratori embed softwar platform manag
analyz data gener balanc titrat ph meter moistur analyz
analyt instrument labx provid full network capabl assist workflow autom
enabl custom collect archiv data complianc food drug administr
fda traceabl requir electron store data
believ labx softwar largest market share analyt instrument softwar
packag research engin familiar labx high level integr laboratori
workflow make custom sticki view gener separ sell
softwar run competitor instrument softwar embed hardwar
industri weigh instrument offer comprehens line industri scale weigh
devic bench scale floor scale weigh modul weigh load gram
sever thousand kilogram industri weigh product use wide rang industri
applic count formul mix ingredi qualiti control
industri termin transport logist vehicl scale system softwar industri
termin allow collect data integr manufactur process help autom
also suppli automat dimension measur data captur solut integr
in-mot weigh dimens identif technolog solut custom
measur weight cubic volum packag appropri bill load manag qualiti
control also produc scale weigh truck railcar heavi industri scale capabl
measur weight ton permit accur weigh extrem environment condit
also provid softwar integr industri analysi product improv
workflow enhanc data collect analysi
impact major develop expect mtd result adversli impact
crisi anticip prolong neg impact mtd chines sale past rest
global oper start late due deepen shock signific
concentr oper china includ manufactur facil advers affect
ban put place chines author keep employe home start earli februari view
also expect disrupt due bottleneck suppli chain custom inabl travel
receiv shipment period
corpor strategi prolif purchas share howev expect halt
compani buy-back activ think prefer preserv cash current environ
due uncertainti stem crisi sinc start buy-back program
decemb made net repurchas provid materi boost ep
financi trend sale increas repres three-year
compound annual growth rate compound-annual-growth-rate period adjust pre-tax incom per share
grown three-year compound-annual-growth-rate earn growth outpac sale growth
due consist share repurchas well adjust pre-tax incom margin improv
indic excel price power view conserv
capit ebita-to-interest moder net debt/ebitda
decemb leav enough cushion absorb potenti headwind view
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
neutral sinc may technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
neutral fundament outlook
life scienc tool servic sub-industri
expect earn growth remain
posit slow sharpli rate achiev
risk factor see slower
biopharmaceut spend growth
prolong uncertainti due
nation institut nih budget
grow rapidli last three
year materi increas fund
academ govern lab turn
help drive sale growth mani lst
compani suppli lab nih fy
sep budget grew vs prior year
follow growth fy
mark major acceler averag growth
fy fy believ
boost sale lst
sub-industri grew
prolifer advanc health care around
world continu drive demand growth
lst firm long-term emerg
market particularli china india
rapidli grow middl class gain
access advanc health care
drive suppli need new expand
medic research lab facil howev
due rapidli spread coronaviru
result suppli chain travel disrupt
expect slowdown demand next
think biopharmaceut firm moder
 spend growth due
outbreak
estim total spend
global biopharmaceut compani grew
annual averag expect slow
see
delay new clinic trial halt
on-go studi major pharmaceut
compani larg swath biopharma
typic flow lst firm suppli
depart research tool softwar
contract servic accordingli think
slowdown biopharma growth
reduc tailwind mani lst firm
receiv client group recent
expect recent coronaviru outbreak
oper result first half
china small promis market
lst compani around total
sector revenu seen number
disrupt due travel restrict
temporari closur site china
expect loss stem chines
oper limit expect
loss increas
time certain lst compani
well-posit benefit outbreak
close work
govern hospit develop test
kit sequenc genom viru
fda issu emerg author
number lst firm diagnost
serolog test use
laboratori detect
consider need respond grow
daili diagnost demand point
 lst compani quickli
absorb demand
year date april
servic declin compar
decreas experienc
broader healthcar sector
decreas overal
index life scienc tool
much faster rise
healthcar sector rise
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
pm et cfra keep hold opinion share mettler-toledo intern
inc keep target ep estim --
within histor forward price-to-earnings averag rang drop ep estim
start adjust
ep beat consensu grew yoy materi faster yoy
revenu growth sale mix shift higher margin product
integr softwar view healthi sale growth laboratori total
yoy industri yoy partli off-set sharp declin
food retail yoy food retail gener substanti revenu
groceri check counter scale demand hurt trend toward
on-line groceri shop view howev see threaten
long-term earn power expect ep grow two larger
segment experi healthi demand growth particularli laboratori due strong
biopharma demand advanc drug prolifer global /colin scarola
et cfra lower opinion health marketweight
overweight lower recommend exposur
sector marketweight overweight group tradit
perform well tradit lacklust summer month keep
pace overal market remaind year besid alreadi
trade elev valuat particularli best perform
sub-industri medic technolog life scienc tool think
group contend increas political/regulatori risk
presidenti elect cycl get full swing final group
below-averag percentag favor constitu invest recommend
analyst research note compani news
et cfra maintain hold opinion share
intern inc lift target
ep estim line mtd histor forward price-to-earnings
averag cut ep estim expect
signific neg impact mtd global oper due
shock cut ep estim ep
vs consensu revenu decreas yoy
neg impact chines sale yoy local currenc
higher expect except america yoy region
oper saw sharp sale declin asia/row impact
yoy follow europ yoy product area food retail sale
significantli impact yoy local currenc follow industri
yoy lab yoy expect sever impact
expect sale declin america also continu weak
europ asia expect china slowli pick sel hardi
pm et cfra keep hold opinion share
intern inc cut target
revis ep estim mtd histor forward price-to-earnings
averag lower ep estim
expect prolong neg impact mtd chines sale past
rest global oper start late due shock
cut ep estim one
largest exposur china among lst compani coverag univers
chines oper made mtd revenu
signific concentr oper china includ
manufactur facil advers affect ban put place
chines author keep employe home view also expect
disrupt due bottleneck suppli chain custom
inabl travel receiv shipment period remain hold
better assess neg impact mtd
et cfra keep hold opinion share
intern inc cut target
ep estim line mtd histor forward price-to-earnings
averag lower ep estim expect
neg impact chines sale first quarter year due
coronaviru outbreak keep ep estim
ep vs yoy beat capit iq consensu
revenu grew yoy driven yoy local currenc sale growth
america yoy growth asia/rest world offset sluggish
european sale yoy local currenc line expect
china record solid yoy growth benefit posit momentum
follow resolut phase-on trade deal howev
expect trend continu due increas risk relat
coronaviru keep hold rate expect signific
out-performance vs market next year /sel hardi
et cfra keep hold opinion share
intern inc rais target price
ep estim line histor forward price-to-earnings
averag maintain ep estim rais target price reflect
improv investor sentiment stock fundament view
stock posit yet see share near full valu expect
signific out-performance vs market next year stock
current benefit posit momentum follow resolut
phase-on deal china although uncertainti remain
detail agreement view posit impact deal
compani two fold import chines product base
largest market total sale year-end
septemb larg presenc china overal market
share total sale year-end septemb /sel hardi
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
